MedTrace Logo

ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01097668 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2015-02-16

Study results available
· View outcomes & findings →

Summary

Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis. This will be an open label upward dose titration involving injections on 9 occasions, each two weeks apart. After dosing is complete there will be a 22 week follow up period. Blood samples will be drawn throughout the study to monitor safety and the body's response to the injections and MRI scans will be performed on several occasions to follow the course of the multiple sclerosis during the trial.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

BIOLOGICAL

ATX-MS-1467

Disease specific immune modulating treatment for multiple sclerosis

Sponsors & Collaborators

  • Aptiv Solutions

    collaborator INDUSTRY

  • ClinStar, LLC

    collaborator INDUSTRY

  • Apitope Technology (Bristol) Ltd.

    lead INDUSTRY

Principal Investigators

  • Jeremy Chataway · National Hospital for Neurology and Neurosurgery, London

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Russia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01097668 on ClinicalTrials.gov